Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-02-2011 | Original Paper

The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey

Authors: M. K. Yazıcı, A. E. Anıl Yağcıoğlu, A. Ertuğrul, N. Eni, S. Karahan, E. Karaağaoğlu, S. L. Tokgözoğlu

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 1/2011

Abstract

Most studies point to an increased prevalence of metabolic syndrome (MS) and an increased risk of coronary heart disease (CHD) in schizophrenia patients with MS. The aims of this study were to compare the prevalence of MS in schizophrenia patients with the general population, to explore the clinical correlates and predictors of MS and to evaluate the risk for CHD within 10 years. Consecutive 319 patients, aged 18–75 years, with a diagnosis of schizophrenia according to the DSM-IV were enrolled. The ATP-III, the ATP-IIIA and the IDF criteria were used to define MS. 10-year risk of CHD events was calculated with the Framingham score. One hundred nine (34.2%) patients met the ATP-III criteria, 118 (37%) the ATP-IIIA and 133 (41.7%) the IDF criteria for MS. Patients with MS were older, had a later onset of illness and an older age at first hospitalization. The prevalence of MS in schizophrenia patients was higher from the general population only within the 20–29 age group. Patients with MS had a higher age and sex-corrected 10-year risk of CHD events. The only predictor of MS was the age of illness onset. In conclusion, countries where the general population prevalence of MS is already too high, schizophrenia patients younger than 30 years of age might be under higher risk of morbidity and mortality related with MS. This study points to the necessity for aggressive interventions to correct MS in schizophrenia as early as possible, within the first 10 years of post detection.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3166CrossRef

Grundy SM, Brewer B, Cleeman JL, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, And Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 109:433–438CrossRefPubMed

IDF (2005) The IDF Consensus Worldwide Definition of the Metabolic Syndrome. International Diabetes Federation, Brussels

Suvisaari J, Perälä J, Saarni SI, Härkänen T, Pirkola S, Joukamaa M, Koskinen S, Lönnqvist J, Reunanen A (2008) Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. Eur Arch Psychiatry Clin Neurosci 258:129–136CrossRefPubMed

Barnett AH, Millar HL, Loze JY, L’Italien GJ, van Baardewijk M, Knapp M (2009) UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study). Eur Arch Psychiatry Clin Neurosci 259:239–247CrossRefPubMed

Leucht S (2009) Physical illness and schizophrenia. Eur Arch Psychiatry Clin Neurosci 259(Suppl 1):S34

Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J (2003) Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575–579CrossRefPubMed

Littrell KH, Petty R, Ortega TR, Moore D, Ballard A, Clough R, Lan TS, Selby C (2003) Insulin resistance and Syndrome X among patients with schizophrenia. Abstract presented at the American Psychiatric Association Annual Meeting, San Francisco

10.

Kato MM, Currier MB, Gomez CM, Hall L, Gonzalez-Blanco M (2004) Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry 6:74–77CrossRefPubMed

11.

Basu R, Brar JS, Chengappa KNR, John V, Parapally H, Gershon S, Schlicht P, Kupfer D (2004) The prevalence of the metabolic syndrome in patients with schizoaffective disorder-bipolar subtype. Bipolar Disord 6:314–318CrossRefPubMed

12.

Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G (2004) Characterizing coronary heart disease risk in schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 49:753–760PubMed

13.

Meyer JM, Pandina G, Bossie CA, Turkoz I, Greenspan A (2005) Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 27:1930–1941CrossRefPubMed

14.

Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin M-R, Lauren LH, Savolainen MJ, Koponen HJ (2005) A 4-fold risk of metabolic syndrome in patients with schizophrenia: the northern Finland 1966 birth cohort study. J Clin Psychiatry 66:559–563CrossRefPubMed

15.

Koponen HJ, Hakko HH, Saari KM, Lindeman SM, Karvonen KM, Isohanni MK, Lauren LH, Savolainen MJ, Jarvelin MR (2008) The prevalence and predictive value of individual criteria for metabolic syndrome in schizophrenia: a Northern Finland 1966 Birth Cohort Study. World J Biol Psychiatry 1–6

16.

McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TS, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32CrossRefPubMed

17.

Hagg S, Lindblom Y, Mjorndal T, Adolfsson R (2006) High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21:93–98CrossRefPubMed

18.

Meyer JM, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, Wirshing D (2006) Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 12:5–10CrossRefPubMed

19.

Correll CU, Frederickson AM, Kane JM, Manu P (2006) Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs. J Clin Psychiatry 67:575–583CrossRefPubMed

20.

Lamberti JS, Olson D, Crilly JF, Olivares T, Williams GC, Tu X, Tang W, Wiener K, Dvorin S, Dietz MB (2006) Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 163:1273–1276CrossRefPubMed

21.

De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83:87–93CrossRefPubMed

22.

Teixeira PJ, Rocha FL (2007) The prevalence of metabolic syndrome among psychiatric inpatients in Brazil. Rev Bras Psiquiatr 29:330–336CrossRefPubMed

23.

Sanchez-Arana Moreno T, Tourino Gonzalez R, Hernandez Fleta JL, Leon Perez P (2007) Prevalence of the metabolic syndrome among schizophrenic patients hospitalized in the Canary Islands. Actas Esp Psiquiatr 35:359–367PubMed

24.

Tirupati S, Chua LE (2007) Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry 15:470–473CrossRefPubMed

25.

Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N (2007) Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 7:14

26.

Kurt E, Altinbas K, Alatas G, Ozver İ (2007) Metabolic syndrome prevalence among schizophrenic patients treated in chronic inpatient clinics. Psychiatry in Türkiye 3:141–145

27.

Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, Study Collaborative Group CLAMORS (2007) Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS study. Schizophr Res 90:162–173CrossRefPubMed

28.

Rejas J, Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M (2008) Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study. Schizophr Res 99:23–28, 26

29.

Saddichha S, Manjunatha N, Ameen S, Akhtar S (2008) Metabolic syndrome in first episode schizophrenia—a randomized double-blind controlled, short-term prospective study. Schizophr Res 101:266–272CrossRefPubMed

30.

Correll CU, Frederickson AM, Kane JM, Manu P (2008) Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics. Bipolar Disord 10:788–797CrossRefPubMed

31.

Cerit C, Ozten E, Yildiz M (2008) The prevalence of metabolic syndrome and related factors in patients with schizophrenia. Turk Psikiyatri Derg 19:124–132PubMed

32.

Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR (2008) Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med 38:103–112CrossRefPubMed

33.

Oyekcin DG (2009) The frequency of metabolic syndrome in patients with schizophrenia and schizoaffective disorder. Anatolian J Psychiatry 10:26–33

34.

Kaya MC, Virit O, Altındağ A, Selek S, Bülbül F, Bulut M, Savaş HA (2009) Prevalence of metabolic syndrome, characteristics of metabolic syndrome and relationship with the antipsychotics used in schizophrenia. Arch Neuropsychiatry 46:13–18

35.

Brunero S, Lamont S, Fairbrother G (2009) Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia. Arch Psychiatr Nurs 23:261–268CrossRefPubMed

36.

Huang MC, Lu ML, Tsai CJ, Chen PY, Chiu CC, Jian DL, Lin KM, Chen CH (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120:274–280CrossRefPubMed

37.

Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D’Agastino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80:45–53CrossRefPubMed

38.

Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; on behalf of the CLAMORS study collaborative group (2008) A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 104:1–12

39.

Kozan O, Oguz A, Abaci A, Erol C, Ongen Z, Temizhan A, Celik S (2007) Prevalence of the metabolic syndrome among Turkish adults. Eur J Clin Nutr 61:548–553PubMed

40.

Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed

41.

Onat A, Sansoy V (2002) Metabolic syndrome, major culprit of coronary disease among Turks: its prevalence and impact on coronary risk. Türk Kardiyol Dern Arş 30:8–15

42.

Straker D, Correll CU, Kramer-Ginsberg E, Abdulhamid N, Koshy F, Rubens E, Saint-Vil R, Kane JM, Manu P (2005) Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 162:1217–1221CrossRefPubMed

43.

De Hert M, Schreurs V, Vancampfort D, Van Winkel RD (2009) Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8:15–22

44.

De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG, Möller HJ (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24:412–424CrossRefPubMed

45.

Haupt DW (2006) Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol 16:S149–S155CrossRefPubMed

46.

De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, Wampers M, Scheen A, Peuskens J, van Winkel R (2008) Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res 101:295–303CrossRefPubMed

47.

Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2008) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101:273–286CrossRefPubMed

48.

Stahl SM, Mignon L, Meyer JM (2009) Which comes first: atypical antipsychotics treatment or cardiometabolic risk? Acta Psychiatr Scand 119:171–179CrossRefPubMed

49.

Simon V, van Winkel R, De Hert M (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70:1041–1050CrossRefPubMed

50.

Bermudes RA, Keck PE Jr, Welge JA (2006) The prevalence of the metabolic syndrome in psychiatric inpatients with primary psychotic and mood disorders. Psychosomatics 47:491–497CrossRefPubMed

Title: The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey
Authors: M. K. Yazıcı
A. E. Anıl Yağcıoğlu
A. Ertuğrul
N. Eni
S. Karahan
E. Karaağaoğlu
S. L. Tokgözoğlu
Publication date: 01-02-2011
Publisher: Springer-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 1/2011
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-010-0118-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Validity of the Definite and Semidefinite Questionnaire version of the Hamilton Depression Scale, the Hamilton Subscale and the Melancholia Scale. Part I

A morphometric analysis of the septal nuclei in schizophrenia and affective disorders: reduced neuronal density in the lateral septal nucleus in bipolar disorder

Negative schizophrenic symptoms and the frontal lobe syndrome: one and the same?

Combining the categorical and the dimensional perspective in a diagnostic map of psychotic disorders

Reappraisal of the interplay between psychosis and depression symptoms in the pathogenesis of psychotic syndromes: results from a twenty-year prospective community study

The psychosis continuum: diagnosis and other phenotypes